Pregnancy on dialysis is increasingly being reported. This study evaluates the behavioural profile of the children of mothers on dialysis and the parental stress their mothers undergo when compared ...with a group of mothers affected by a different chronic disease (microcythaemia) and a group of healthy control mothers.
Between 2000 and 2012, 23 on-dialysis mothers gave birth to 24 live-born children in Italy (23 pregnancies, 1 twin pregnancy, one of the twins deceased soon after delivery); of these, 16 mothers and 1 father (whose wife died before the inquiry) were included in the study (1 mother had died and the father was unavailable; 2 were not asked to participate because their children had died and 3 were unavailable; children: median age: 8.5, min-max: 2-13 years). Twenty-three mothers affected by transfusion-dependent microcythaemia or drepanocitosis (31 pregnancies, 32 children) and 35 healthy mothers (35 pregnancies, 35 children; median age of the children: 7, min-max: 1-13 years) were recruited as controls. All filled in the validated questionnaires: 'Child Behaviour Checklist' (CBCL) and the 'Parental Stress Index-Short Form' (PSI-SF).
The results of the CBCL questionnaire were similar for mothers on dialysis and healthy controls except for pervasive developmental problems, which were significantly higher in the dialysis group, while microcythaemia mothers reported higher emotional and behavioural problems in their children in 8 CBCL sub-scales. Two/16 children in the dialysis and 3/32 in the microcythaemia group had pathological profiles, as assessed by T-scores (p: ns). PSI-SF indicated a normal degree of parental stress in microcythaemia subjects and healthy controls, while mothers on dialysis declared significantly lower stress, suggesting a defensive response in order to minimize problems, stress or negativity in their relationship with their child.
According to the present analysis, the emotional and behavioural outcome is normal in most of the children from on-dialysis mothers. A 'positive defence' in the dialysis mothers should be kept in mind when tailoring psychological support for this medical miracle.
ADPKD treatment: Tolvaptan and Octreotide Galliani, Marco; Chicca, Silvana; Vitaliano, Elio ...
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia,
2019-Dec-09, Letnik:
36, Številka:
6
Journal Article
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most frequent monogenic hereditary disease as well as the most studied inherited kidney disease. Two drugs have recently been authorized ...that can slow down the progression of the disease: Tolvaptan (vasopressin receptor antagonist) and Octreotide-LAR (long-acting somatostatin analogue); they both are able to reduce the activity of cyclic adenosine monophosphate (cAMP) and therefore have anti-proliferative and anti-secretory effects. This review analyzes the main trials published to date demonstrating the effects on disease progression in patients with ADPKD and illustrates the indications for identifying subjects eligible for therapy.
Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population.
In a ...multicenter, case-control, retrospective, observational study, sitagliptin, an oral and highly selective dipeptidyl peptidase 4 inhibitor, was added to standard of care (e.g., insulin administration) at the time of hospitalization in patients with type 2 diabetes who were hospitalized with COVID-19. Every center also recruited at a 1:1 ratio untreated control subjects matched for age and sex. All patients had pneumonia and exhibited oxygen saturation <95% when breathing ambient air or when receiving oxygen support. The primary end points were discharge from the hospital/death and improvement of clinical outcomes, defined as an increase in at least two points on a seven-category modified ordinal scale. Data were collected retrospectively from patients receiving sitagliptin from 1 March through 30 April 2020.
Of the 338 consecutive patients with type 2 diabetes and COVID-19 admitted in Northern Italy hospitals included in this study, 169 were on sitagliptin, while 169 were on standard of care. Treatment with sitagliptin at the time of hospitalization was associated with reduced mortality (18% vs. 37% of deceased patients; hazard ratio 0.44 95% CI 0.29-0.66;
= 0.0001), with an improvement in clinical outcomes (60% vs. 38% of improved patients;
= 0.0001) and with a greater number of hospital discharges (120 vs. 89 of discharged patients;
= 0.0008) compared with patients receiving standard of care, respectively.
In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment. The effects of sitagliptin in patients with type 2 diabetes and COVID-19 should be confirmed in an ongoing randomized, placebo-controlled trial.
This study aimed to report the spectrum of placental pathology findings in pregnancies complicated by SARS-CoV-2 infection.
MEDLINE, Embase, Google Scholar, and the Web of Science databases were ...searched up to August 11, 2021.
Histopathologic anomalies included maternal vascular malperfusion, fetal vascular malperfusion, acute inflammatory pathology, chronic inflammatory pathology, increased perivillous fibrin, and intervillous thrombosis. Moreover, subanalyses of symptomatic women only and high-risk pregnancies were performed. METHODS: Histopathologic analysis of the placenta included gross examination, histopathology on hematoxylin and eosin, immunohistochemistry, fluorescence in situ hybridization, quantitative reverse transcription-polymerase chain reaction on placental tissue, and transmission electron microscope. Random-effect meta-analyses were used to analyze the data.
A total of 56 studies (1008 pregnancies) were included. Maternal vascular malperfusion was reported in 30.7% of placentas (95% confidence interval, 20.3–42.1), whereas fetal vascular malperfusion was observed in 27.08 % of cases (95% confidence interval, 19.2–35.6). Acute and chronic inflammatory pathologies were reported in 22.68% (95% confidence interval, 16.9–29.0) and 25.65% (95% confidence interval, 18.4–33.6) of cases, respectively. Increased perivillous fibrin was observed in 32.7% (95% confidence interval, 24.1–42.0) of placentas undergoing histopathologic analysis, whereas intervillous thrombosis was observed in 14.6% of cases (95% confidence interval, 9.7–20.2). Other placental findings, including a basal plate with attached myometrial fibers, microscopic accretism, villous edema, increased circulating nucleated red blood cells, or membranes with hemorrhage, were reported in 37.5% of cases (95% confidence interval, 28.0–47.5), whereas only 17.5% of cases (95% confidence interval, 10.9–25.2) did not present any abnormal histologic findings. The subanalyses according to maternal symptoms owing to SARS-CoV-2 infection or the presence of a high-risk pregnancy showed a similar distribution of the different histopathologic anomalies to that reported in the main analysis. Moreover, the risk of placental histopathologic anomalies was higher when considering only case-control studies comparing women with SARS-CoV-2 infection with healthy controls.
In pregnant women with SARS-CoV-2 infection, a significant proportion of placentas showed histopathologic findings, suggesting placental hypoperfusion and inflammation. Future multicenter prospective blinded studies are needed to correlate these placental lesions with pregnancy outcomes.
To explore maternal and perinatal outcomes of women undergoing full dilatation cesarean section (CS) who had compared to those who did not have application of fetal head elevation device (FHED).
...Pubmed, Embase, Cinahl, Clinical Trial.Gov and Google Scholar databases were searched. Inclusion criteria were studies exploring maternal and perinatal outcomes in women having compared to those not having FHED at full dilatation CS. The outcomes explored were: hysterotomy to delivery time (sec), mean estimated blood loss (ml), blood loss > 1000 mL, need for blood transfusion, uterine incision extension, operative complications, need for re-operation, urinary retention, hospital re-admission, length of in hospital stay, Apgar score < 3 at 1 min, Apgar score < 7 at 5 min, neonatal arterial Ph, arterial pH < 7.1, admission to neonatal intensive care unit (NICU), neonatal sepsis, need for neonatal endotracheal intubation, neonatal death. Random effect head-to-head meta-analyses combining summary mean difference (MD), and odd ratio (OR) were used to analyze the data.
Ten studies (1326 women) were included. The mean time from hysterotomy to delivery was lower in women having compared to those not having FHED (MD: -52.26 s, 95 % CI -55.2 to -34.94, p < 0.001). Women who had FHED had also a lower mean estimated blood loss (MD: -130.82 mL, 95 % CI -130.1 to -381.0; p < 0.001) and a shorter stay in the hospital (MD: -0.884 h, 95 % CI -1.07 to -0.70; p < 0.001) compared to controls. Pregnant women having FHED at full dilatation CS had a lower risk of uterine incision extension (OR: 0.50, 95 % CI 0.3 to 0.9; p = 0.02), need for blood transfusion (OR: 0.39, 95 % CI 0.2 to 0.7; p = 0.04) and operative complications (OR: 0.44, 95 % CI 0.2 to 0.9; p = 0.03) compared to controls, while there was no difference in the other maternal outcomes between the two groups. When exploring perinatal outcome, women who received FHED had higher mean arterial pH values (MD: 0.617, 95 % CI 0.43 to 0.88; p < 0.001) and a lower risk of neonatal sepsis (OR: 0.10, 95 % CI 0.01 to 0.99; p = 0.05) and admission to NICU (OR: 0.63, 95 % CI 0.5 to 0.9; p = 0.008) compared to controls.
Application of FHED at full dilatation CS seems to be associated with improvement in some maternal and neonatal outcomes.
The future power system, characterized by lower inertia, reduced programmability and more distributed architecture, will depend on prompt and reliable control systems. Quick ancillary services ...provided by battery energy storage systems (BESS) could be a resource in order to deliver fast and precise response to frequency events. Degrees of freedom in the design of innovative products traded on ancillary services markets give the asset manager room for developing state-of-charge (SoC) restoration mechanisms. These are necessary to effectively exploit BESS as key resources for electricity balancing. This study compares the main SoC restoration strategies. It aims to define which ones are suitable for guaranteeing the reliability of the provision and the return on the investment. A robust regulatory framework analysis describes the degrees of freedom guaranteed by the main experiences around Europe. In this paper, a BESS model with variable efficiency is used to compare the provision of Frequency Containment Reserve (FCR) with different SoC restoration strategies exploiting one or more degrees of freedom. Here, we show that the degrees of freedom are key to the reliability of provision. Among most diffused mechanisms, dead-band strategies secure the desired consistency, but require large energy flows for SoC management. Thus, BESS life and economics decrease. The strategies based on minimum available energy guarantee assured reliability while being fair with BESS life and operation costs.
Coeliac disease and dermatitis herpetiformis are immune-mediated diseases triggered by the consumption of gluten in genetically predisposed individuals. These guidelines were developed to provide ...general practitioners, paediatricians, gastroenterologists, and other clinicians with an overview on the diagnosis, management and follow-up of coeliac patients and those with dermatitis herpetiformis.
Guidelines were developed by the Italian Societies of Gastroenterology. Following a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the certainty of the evidence. Statements and recommendations were developed by working groups consisting of gastroenterologists and a paediatrician with expertise in this field.
These guidelines provide a practical guidance for the diagnosis, management and follow-up of coeliac patients and dermatitis herpetiformis in children and adults, both in primary care and in specialist settings. We developed four sections on diagnosis, gluten-free diet, follow-up and risk of complications in adults, one section focused on diagnosis and follow-up in children and one on the diagnosis and management of dermatitis herpetiformis.
These guidelines may support clinicians to improve the diagnosis and management of patients with coeliac disease.
Lysosomal storage disorders (LSDs) result from an enzyme deficiency within lysosomes. The systemic administration of the missing enzyme, however, is not effective in the case of LSDs with central ...nervous system (CNS)-involvement. Here, an enzyme delivery system based on the encapsulation of cross-linked enzyme aggregates (CLEAs) into poly-(lactide-co-glycolide) (PLGA) nanoparticles (NPs) functionalized with brain targeting peptides (Ang2, g7 or Tf2) is demonstrated for Krabbe disease, a neurodegenerative LSD caused by galactosylceramidase (GALC) deficiency. We first synthesize and characterize Ang2-, g7- and Tf2-targeted GALC CLEA NPs. We study NP cell trafficking and capability to reinstate enzymatic activity in vitro. Then, we successfully test our formulations in the Twitcher mouse. We report enzymatic activity measurements in the nervous system and in accumulation districts upon intraperitoneal injections, demonstrating activity recovery in the brain up to the unaffected mice level. Together, these results open new therapeutic perspectives for all LSDs with major CNS-involvement.
PDF
